These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16857690)

  • 61. Tuberculosis Schemes-Administrator and Clinician.
    Macgregor ASM
    Edinb Med J; 1932 Mar; 39(3):126-130. PubMed ID: 29640625
    [No Abstract]   [Full Text] [Related]  

  • 62. Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs.
    Davies G; Boeree M; Hermann D; Hoelscher M
    PLoS Med; 2019 Jul; 16(7):e1002851. PubMed ID: 31287813
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.
    Milstein M; Lecca L; Peloquin C; Mitchison D; Seung K; Pagano M; Coleman D; Osso E; Coit J; Vargas Vasquez DE; Sanchez Garavito E; Calderon R; Contreras C; Davies G; Mitnick CD
    BMC Infect Dis; 2016 Aug; 16(1):453. PubMed ID: 27567500
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pharmacodynamic Modeling of Bacillary Elimination Rates and Detection of Bacterial Lipid Bodies in Sputum to Predict and Understand Outcomes in Treatment of Pulmonary Tuberculosis.
    Sloan DJ; Mwandumba HC; Garton NJ; Khoo SH; Butterworth AE; Allain TJ; Heyderman RS; Corbett EL; Barer MR; Davies GR
    Clin Infect Dis; 2015 Jul; 61(1):1-8. PubMed ID: 25778753
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Bayesian Nonlinear Mixed-Effects Regression Model for the Characterization of Early Bactericidal Activity of Tuberculosis Drugs.
    Burger DA; Schall R
    J Biopharm Stat; 2015; 25(6):1247-71. PubMed ID: 25322214
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Alternative strategies for proof-of-principle studies of antibacterial agents.
    Dalhoff A; Weintraub A; Nord CE
    Antimicrob Agents Chemother; 2014 Aug; 58(8):4257-63. PubMed ID: 24867989
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Assessment of the Efficacy of New Anti-Tuberculosis Drugs.
    Mitchison DA; Davies GR
    Open Infect Dis J; 2008 Dec; 2():59-76. PubMed ID: 23814629
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture.
    Chigutsa E; Patel K; Denti P; Visser M; Maartens G; Kirkpatrick CM; McIlleron H; Karlsson MO
    Antimicrob Agents Chemother; 2013 Feb; 57(2):789-95. PubMed ID: 23183433
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Optimizing outpatient serial sputum colony counting for studies of tuberculosis treatment in resource-poor settings.
    Sloan DJ; Corbett EL; Butterworth AE; Mwandumba HC; Khoo SH; Mdolo A; Shani D; Kamdolozi M; Allen J; Mitchison DA; Coleman DJ; Davies GR
    J Clin Microbiol; 2012 Jul; 50(7):2315-20. PubMed ID: 22573593
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The immunology of tuberculosis: from bench to bedside.
    Dheda K; Schwander SK; Zhu B; van Zyl-Smit RN; Zhang Y
    Respirology; 2010 Apr; 15(3):433-50. PubMed ID: 20415982
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tuberculosis pharmacotherapy: strategies to optimize patient care.
    Mitnick CD; McGee B; Peloquin CA
    Expert Opin Pharmacother; 2009 Feb; 10(3):381-401. PubMed ID: 19191677
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The early bactericidal activity of anti-tuberculosis drugs: a literature review.
    Donald PR; Diacon AH
    Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S75-83. PubMed ID: 18762155
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A multicentre comparison of a novel surrogate marker for determining the specific potency of anti-tuberculosis drugs.
    Gosling RD; Heifets L; Gillespie SH
    J Antimicrob Chemother; 2003 Sep; 52(3):473-6. PubMed ID: 12888596
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity.
    Davies GR
    Tuberculosis (Edinb); 2010 May; 90(3):171-6. PubMed ID: 20382567
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Optimal sampling strategies for early pharmacodynamic measures in tuberculosis.
    Davies GR; Khoo SH; Aarons LJ
    J Antimicrob Chemother; 2006 Sep; 58(3):594-600. PubMed ID: 16857690
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical development of anti-tuberculosis drugs.
    Mitchison DA
    J Antimicrob Chemother; 2006 Sep; 58(3):494-5. PubMed ID: 16840430
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears.
    Diacon AH; Patientia RF; Venter A; van Helden PD; Smith PJ; McIlleron H; Maritz JS; Donald PR
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2994-6. PubMed ID: 17517849
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.